

Product Datasheet

Fibrinogen Antibody NBP2-80414

Unit Size: 100 ul

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 2

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP2-80414

Updated 9/9/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP2-80414



NBP2-80414

Fibrinogen Antibody


Product Information	
Unit Size	100 ul
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.05% Sodium Azide
Isotype	IgG
Purity	Protein A purified
Buffer	PBS (pH7.4), 0.2% BSA, 50% Glycerol
Target Molecular Weight	70 kDa

Product Description	
Description	Novus Biologicals Rabbit Fibrinogen Antibody (NBP2-80414) is a polyclonal antibody validated for use in IHC, WB, Flow and ICC/IF. Anti-Fibrinogen Antibody: Cited in 2 publications. All Novus Biologicals antibodies are covered by our 100% guarantee.
Host	Rabbit
Gene ID	2243
Gene Symbol	FGA
Species	Human, Mouse
Immunogen	Native protein. (SwissProt: P02671; SwissProt: P0267 Human 5; SwissProt: P02679 Human)


Product Application Details	
Applications	Western Blot, Flow Cytometry, Immunocytochemistry/ Immunofluorescence
Recommended Dilutions	Western Blot 1:500, Flow Cytometry 1:50-1:100, Immunocytochemistry/ Immunofluorescence 1:100-1:500

Images


Western Blot: Fibrinogen Antibody [NBP2-80414] - Analysis of Fibrinogen on mouse bone marrow and human kidney tissue lysates using anti-Fibrinogen antibody at 1/500 dilution.




Immunocytochemistry/Immunofluorescence: Fibrinogen Antibody [NBP2-80414] - Staining Fibrinogen in A549 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.




Flow Cytometry: Fibrinogen Antibody [NBP2-80414] - Analysis of NIH-3T3 cells with Fibrinogen antibody at 1/100 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black). Alexa Fluor 488-conjugated goat anti-rabbit IgG was used as the secondary antibody.




Immunocytochemistry/Immunofluorescence: Fibrinogen Antibody [NBP2-80414] - Staining Fibrinogen in NIH-3T3 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100/PBS.




Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri-infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μ m. (B) Quantification of fibrinogen immunoreactivity in the peri-infarct areas per area. (C) Scheme illustrating MCAO on anandamide-administered mice. (D) Enzyme-linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μ m. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μ m. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μ m. N = 6 mice. Data are presented as mean \pm SEM, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Fibrinogen inhibits remyelination after MCAO and disrupts OPC differentiation by activating ACVR1. (A) MBP (red) and fibrinogen (green) immunostaining in the peri-infarct areas 7 days after MCAO. Scale bar, 50 μ m. (B) Quantification of MBP immunoreactivity in the peri-infarct areas per area. N = 6 mice. (C) MBP mRNA expression. N = 6 mice. (D) Transmission electron microscope analysis was performed on the peri-infarct areas. Scale bar, 1 μ m (top), 0.5 μ m (bottom). (E) Quantification of the myelinated axons (% of total axons). N = 6 mice. (F) Volcano plot of differentially expressed genes. Red points represent upregulated genes, blue points represent downregulated genes, and gray points represent the unchanged genes. (G) Heatmap of differentially expressed genes in untreated OPCs and fibrinogen-treated OPCs. N = 3 per group. (H) The verification of ACVR1 mRNA expression. N = 6 per group. Data are presented as mean \pm SEM, one-way ANOVA, or unpaired Student's t-test, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri-infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μ m. (B) Quantification of fibrinogen immunoreactivity in the peri-infarct areas per area. (C) Scheme illustrating MCAO on ancrodo-administered mice. (D) Enzyme-linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μ m. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μ m. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μ m. N = 6 mice. Data are presented as mean \pm SEM, one-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.




miR-128-3p mediates OPC differentiation by targeting fibrinogen-BMP signaling. (A) Immunoblot analysis for Lef1 and P-Smad1/5 after MCAO treated with fibrinogen or ancrodo. (B and C) Quantification of Lef1 and P-Smad1/5 expression. N = 6 mice. (D) Id2 (red) and fibrinogen (green) immunostaining. Scale bar, 50 μ m. (E) Quantification of Id2 immunoreactivity. N = 6 mice. (F) Comparison of miRNAs expression in fibrinogen-treated OPCs and untreated OPCs by miRNAs sequencing. N = 3 per group. (G) Venn diagram displaying miR-128-3p computationally predicted targets by three different prediction algorithms: targetScan, starbase, and miRWalk. (H) The verification of miR-128-3p relative expression by qRT-PCR analysis. N = 6 per group. Data are presented as mean \pm SEM, one-way ANOVA or unpaired Student's t-test, **p < 0.01, ***p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri-infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μ m. (B) Quantification of fibrinogen immunoreactivity in the peri-infarct areas per area. (C) Scheme illustrating MCAO on anicrod-administered mice. (D) Enzyme-linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μ m. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μ m. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μ m. N = 6 mice. Data are presented as mean \pm SEM, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Fibrinogen deposition after ischemia. (A) Fibrinogen immunostaining (green) in the peri-infarct areas at 1, 3, 7, and 14 days after MCAO and uninjured mice. Scale bar, 50 μ m. (B) Quantification of fibrinogen immunoreactivity in the peri-infarct areas per area. (C) Scheme illustrating MCAO on anicrod-administered mice. (D) Enzyme-linked immunosorbent assay quantification of fibrinogen. (E) Nestin (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of nestin and fibrinogen. Scale bar, 25 μ m. (F) GFAP (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of GFAP and fibrinogen. Scale bar, 25 μ m. (G) Iba1 (red) and fibrinogen (green) immunostainings in the peri-infarct areas 3 days after MCAO. White arrowheads show the colocalization of Iba1 and fibrinogen. Scale bar, 25 μ m. N = 6 mice. Data are presented as mean \pm SEM, one-way ANOVA, * p < 0.05, ** p < 0.01, *** p < 0.001. Image collected and cropped by CiteAb from the following open publication (<https://pubmed.ncbi.nlm.nih.gov/36756722>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Shu Y, Peng F, Zhao B et al. Transfer of patient's peripheral blood mononuclear cells (PBMCs) disrupts blood-brain barrier and induces anti-NMDAR encephalitis: a study of novel humanized PBMC mouse model *Journal of neuroinflammation* 2023-07-13 [PMID: 37443034] (IHC, Mouse)

Hou H, Wang Y, Yang L, Wang Y Exosomal miR-128-3p reversed fibrinogen-mediated inhibition of oligodendrocyte progenitor cell differentiation and remyelination after cerebral ischemia *CNS neuroscience & therapeutics* 2023-02-08 [PMID: 36756722] (IHC-P, Mouse)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP2-80414

NBP2-33376H	Blue Marker Antibody (6F4-F6) [HRP]
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP2-80414

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

